Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-05-17 16:51
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-05-06 08:30
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer 2021-04-15 08:36
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer 2021-04-14 21:33
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer 2021-04-09 08:30
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression 2021-03-31 10:27
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020 2021-03-22 15:06
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections 2021-03-22 10:40
Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021 2021-03-19 14:43
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited 2021-03-01 12:36
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer 2021-02-18 12:26
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer 2021-02-18 12:21
Everest Medicines Announces Amended Agreement with Spero Therapeutics 2021-01-18 18:05
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer 2021-01-06 21:54
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer 2021-01-06 21:52
CBC-incubated Everest Medicines Successfully Lists on HKEX 2020-10-09 09:31
1 3 4 5 6 7